The recent success of capivasertib in ER-positive/HER2-negative advanced breast cancer has not yet led to any registered studies in HER2-positive breast cancer, but a phase I study has completed accrual to evaluate the safety of capivasertib with T-DXd in HER2-low breast cancer (NCT04556773) [113]. This evidence concerns the gene ERBB2 and breast cancer.